NovaBay Pharmaceuticals, Inc.

Form 4

September 03, 2008

septemoer o	5, 2000												
<b>FORM</b>	14	CEL ENT							OMB AF	PPROVAL			
	Washington, D.C. 20549							COMMISSION	OMB Number:	3235-0287			
Check th if no long	~~*								Expires:	January 31,			
subject to Section 1 Form 4 c	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									Estimated average burden hours per response 0.5			
Form 5 obligatio may contain See Instruction 1(b).	ns Section 17(	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section											
(Print or Type l	Responses)												
Dailley Anthony Symbo			Symbol	Name <b>and</b> y Pharma				5. Relationship of Reporting Person(s) to Issuer					
	[NBY]	y i marma	ccuticats	, inc.		(Check all applicable)							
(Last) (First) (Middle)			3. Date of (Month/D	Earliest Tra ay/Year)	ansaction			X Director 10% Owner Officer (give title below) Other (specify below)					
	BAY CEUTICALS, INC STREET SUITE :		09/03/20	008				ociow)	below)				
	(Street) 4. If Amer Filed(Mon				te Original			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
EMERYVII	LLE, CA 94608							Form filed by M Person	fore than One Re	porting			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed of	, or Beneficial	ly Owned			
1.Title of Security (Month/Day/Year) (Instr. 3)  2. Transaction Date 2A. Deemed Execution Date 2A. Deemed (Month/Day/Year) (Month/Day/Year)			on Date, if	3. Transactio Code (Instr. 8)	(A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) Indirect (I) (Instr. 4)  7. Nature of Beneficial Ownership (Instr. 4)				
Common Stock	08/28/2008			A	15,000	A	\$ 0.56	161,047	I	By the Anthony & Terry Dailley Trust, u/a/d/ 1991			
Common Stock								75,000	D				
								10,180	I				

Common Stock

By the Anthony Dailley DDS Profit Sharing Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Option

(right to \$ 0.56 08/28/2008 buy)

M

15,000 05/01/2004 04/30/2014

Common Stock 15,000

**Reporting Owners** 

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Dailley Anthony C/O NOVABAY PHARMACEUTICALS, INC 5980 HORTON STREET SUITE 550 EMERYVILLE, CA 94608

X

Reporting Owners 2

Date

## **Signatures**

/s/ Theresa Granados, Attorney-in-Fact for Anthony
Dailley

09/03/2008

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3